$23.38 Million in Sales Expected for Nektar Therapeutics (NASDAQ:NKTR) This Quarter

Wall Street brokerages expect Nektar Therapeutics (NASDAQ:NKTRGet Rating) to report $23.38 million in sales for the current quarter, according to Zacks. Six analysts have issued estimates for Nektar Therapeutics’ earnings. The lowest sales estimate is $21.29 million and the highest is $26.60 million. Nektar Therapeutics posted sales of $23.65 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 1.1%. The business is expected to report its next earnings results on Monday, January 1st.

On average, analysts expect that Nektar Therapeutics will report full year sales of $125.83 million for the current fiscal year, with estimates ranging from $90.00 million to $188.00 million. For the next year, analysts anticipate that the firm will post sales of $244.76 million, with estimates ranging from $90.00 million to $852.67 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that follow Nektar Therapeutics.

Nektar Therapeutics (NASDAQ:NKTRGet Rating) last announced its earnings results on Monday, February 28th. The biopharmaceutical company reported ($0.79) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.81) by $0.02. Nektar Therapeutics had a negative net margin of 514.03% and a negative return on equity of 61.98%. The company had revenue of $25.00 million for the quarter, compared to analysts’ expectations of $25.33 million. During the same period last year, the firm earned ($0.65) earnings per share. The business’s revenue for the quarter was up 6.4% on a year-over-year basis.

Several research analysts have recently commented on the stock. Bank of America cut shares of Nektar Therapeutics from a “neutral” rating to an “underperform” rating and lowered their target price for the stock from $18.00 to $6.00 in a report on Monday, March 14th. JPMorgan Chase & Co. decreased their price objective on shares of Nektar Therapeutics from $24.00 to $17.00 in a research note on Tuesday, March 1st. Canaccord Genuity Group decreased their price objective on shares of Nektar Therapeutics from $25.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, March 16th. SVB Leerink decreased their price objective on shares of Nektar Therapeutics from $18.00 to $7.00 and set a “market perform” rating on the stock in a research note on Tuesday, March 15th. Finally, Canaccord Genuity Group decreased their price objective on shares of Nektar Therapeutics from $25.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, March 16th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Nektar Therapeutics presently has an average rating of “Hold” and a consensus target price of $14.58.

Shares of NKTR traded up $0.09 during mid-day trading on Monday, hitting $5.60. 3,470,365 shares of the company’s stock were exchanged, compared to its average volume of 2,963,701. Nektar Therapeutics has a 52 week low of $3.88 and a 52 week high of $20.66. The stock’s 50-day simple moving average is $8.36 and its 200-day simple moving average is $12.08. The firm has a market cap of $1.04 billion, a price-to-earnings ratio of -1.96 and a beta of 1.29.

In other news, insider Jonathan Zalevsky sold 10,912 shares of Nektar Therapeutics stock in a transaction on Wednesday, February 16th. The shares were sold at an average price of $10.95, for a total transaction of $119,486.40. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP John Northcott sold 4,852 shares of Nektar Therapeutics stock in a transaction on Wednesday, February 16th. The stock was sold at an average price of $10.95, for a total transaction of $53,129.40. The disclosure for this sale can be found here. Insiders sold 38,186 shares of company stock worth $418,137 in the last 90 days. Company insiders own 2.91% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in NKTR. Royal Bank of Canada lifted its holdings in Nektar Therapeutics by 155.7% in the second quarter. Royal Bank of Canada now owns 14,087 shares of the biopharmaceutical company’s stock valued at $242,000 after buying an additional 8,578 shares during the period. Bank of America Corp DE lifted its holdings in Nektar Therapeutics by 16.5% in the second quarter. Bank of America Corp DE now owns 130,880 shares of the biopharmaceutical company’s stock valued at $2,247,000 after buying an additional 18,506 shares during the period. Thrivent Financial for Lutherans lifted its holdings in Nektar Therapeutics by 23.2% in the second quarter. Thrivent Financial for Lutherans now owns 59,679 shares of the biopharmaceutical company’s stock valued at $1,024,000 after buying an additional 11,246 shares during the period. Pacer Advisors Inc. lifted its holdings in Nektar Therapeutics by 49.4% in the third quarter. Pacer Advisors Inc. now owns 28,689 shares of the biopharmaceutical company’s stock valued at $515,000 after buying an additional 9,491 shares during the period. Finally, Franklin Street Advisors Inc. NC lifted its holdings in Nektar Therapeutics by 100.0% in the third quarter. Franklin Street Advisors Inc. NC now owns 31,000 shares of the biopharmaceutical company’s stock valued at $557,000 after buying an additional 15,500 shares during the period. Institutional investors and hedge funds own 91.96% of the company’s stock.

Nektar Therapeutics Company Profile (Get Rating)

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19.

Further Reading

Get a free copy of the Zacks research report on Nektar Therapeutics (NKTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.